Corcept Therapeutics
CORT
208 hedge funds and large institutions have $1.59B invested in Corcept Therapeutics in 2021 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 61 increasing their positions, 87 reducing their positions, and 25 closing their positions.
32% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 25
25% more call options, than puts
Call options by funds: $57M | Put options by funds: $45.7M
3% more funds holding
Funds holding: 201 → 208 (+7)
0% more capital invested
Capital invested by funds: $1.59B → $1.59B (+$3.52M)
0.03% more ownership
Funds ownership: 69.76% → 69.78% (+0.03%)
30% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 87
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$65.1M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$15.5M |
| 3 |
EIP
Epoch Investment Partners
New York
|
+$5.29M |
| 4 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$5.17M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$5.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$21.8M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$20.3M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$14.5M |
| 4 |
BlackRock
New York
|
-$11.1M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$6.98M |
CORT Hedge Fund Activity: Q4 2021 in Review
208 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q4 2021, worth a combined $1.59B — up 0.22% from $1.59B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new CORT positions and 25 closed out — a net gain of 8 holders — while 61 added to existing stakes and 87 trimmed.
The largest buyer was Millennium Management, adding an estimated $65.1M. The largest seller was Vanguard Group, cutting an estimated $21.8M.
- 208 institutional investors held Corcept Therapeutics (CORT) as of Q4 2021, up from 201 in Q3 2021.
- Funds reported $1.59B of Corcept Therapeutics stock for Q4 2021, up 0.22% quarter-over-quarter.
- 33 funds opened new Corcept Therapeutics positions in Q4 2021 and 25 closed out, a net change of +8 holders.
- The largest Corcept Therapeutics buyer in Q4 2021 was Millennium Management, an estimated $65.1M added.
- The largest Corcept Therapeutics seller in Q4 2021 was Vanguard Group, an estimated $21.8M sold.
Based on aggregated 13F filings for Q4 2021.